Awards, Honors, and Recognition
2022
Sanofi Performance Recognition Awards:
“Act of Patients and Custmors”. Citation “Tolebrutinib BRAC Analyses and Strategy: Excellence of input to the preparation and presentation of Tolebrutinib safety information and analyses”
2021
Sanofi Performance Recognition Awards:
“Breakthrough Teamwork Award”. Citation: “Leadership Contributions to Tolebrutinib Pharmacovigilance Management and Reporting”
“Breakthrough Teamwork Award”. Citation: “Lemtrada Pregnancy Registry and new PMR”. “Thanks for working all the way together to make the impossible mission successful. Thanks for authoring the draft, searching the available useful data, play brainstorm and convincing the management team and comment on the writings.”
“Development Award”. As a member of the team supporting the Aubagio pediatric indication, won a Development Award in the “Most Innovative and Above & Beyond for Patients” category
“Breakthrough Teamwork Award”. Citation: “Excellence in conceptualization and delivery of Safety Topic Training Presentation Series”
“Think Sanofi First Award”. Citation: “Supporting GPV Learning Solutions: Thank you for your support in the development and execution of the GPV Learning Solutions. Your contributions as an SME for the Structured Benefit-Risk Assessment (sBRA) Advanced Learning Journey, Intermediate sBRA Learning Journey, and the Foundational Benefit-Risk Solutions is very appreciated by me and our PV associates! I look forward to continuing to collaborate with you”
2020
Sanofi Performance Recognition Awards:
“Breakthrough Teamwork Award”. Citation: “Aubagio PASS Report Contributions leading to PRAC endorsement”
“Think Sanofi First Award”. Citation: “Seek what is best for Sanofi and help colleagues achieve success”
2019
Sanofi Performance Recognition Award: “Breakthrough Teamwork Award”. Citation: “Thank you for your excellent contributions to the Lemtrada B/R Article 20 response!”
2013
FDA "Outstanding Service Award”. From the Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services.
FDA Group Recognition Award. citation “as a member of the Medical Isotope Contamination Investigation Group For outstanding efforts to investigate excessive radioactive contamination associated with the PET medical isotope Rubidium-82 resulting in a global recall.”
CDER Excellence in Mentoring. Citation”For volunteering to mentor unprecedented number of interns and fellows (10) in the Office of Surveillance and Epidemiology during the last few years.”
CDER Certificate of Appreciation. Citation “For service and dedication to the CDER Training Program.”
2012
FDA Group Recognition Award for Sentinel Initiative Development Team. Citation “For outstanding commitment to FDA’s mission through implementation of the Sentinel System and exceeding the congressionally mandated deadlines for access to electronic health data.”
CDER Frances O. Kelsey Drug Safety Excellence Award. Citation “For demonstrating exemplary support for FDA drug safety initiatives through exceptional effort and skill in communicating epidemiology concepts pertinent to post-market safety to CDER staff.”
CDER Team Excellence Award. Citation “For the development of an innovative, computerized Project and Assignment Tracking System (PATS) to streamline project management and expedite the promotion of public health.”
CDER Team Excellence Award. Citation “For providing unwavering support and exceptional guidance to the Center for Drug Evaluation and Research while promoting the FDA’s public mission to health.”
2011
CDER "Regulatory Science Excellence Award". Thiazolidinedione Observational Study Systematic Review Team. Citation "For exceptional team and scientific excellence in the successful completion and public presentation of a Cochrane-type systematic review of cardiovascular risk with thiazolidinedione drugs."
FDA "Outstanding Intercenter Science Collaboration". Citation "For collaboratively and innovatively evaluating efficiency of computational resources, leveraging inter-center strengths, to launch post market data evaluation capabilities into the 21st century."
2010
Food and Drug Administration “EXCELLENCE IN ANALYTICAL SCIENCE”. Citation “for developing and applying a novel approach to electronic medical records in order to explore the onset of acute myocardial infarction after use of non-steroidal anti-inflammatory drugs”.
“TEAM EXCELLENCE AWARD”. From the Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services. Citation “for exceptional effort developing a two-month “Epidemiology for non-Epidemiologist” course that provided vital information for interpreting clinical studies examining drug safety questions”.
2009
Food and Drug Administration “COMMISIONER’S SPECIAL CITATION”. Citation “as a member of the heparin task force for prolonged, intense, and innovative response to an international heparin contamination crisis”.
Tarek A Hammad, Graham DJ, Staffa JA, Kornegay CJ, Dal Pan G. “Onset of Acute Myocardial Infarction After Use of Non-steroidal Anti-inflammatory Drugs”. Pharmacoepidemiol Drug Saf. 2008 Apr;17(4):315-21. The paper won an award as "one of the best papers published in Pharmacoepidemiology and Drug Safety (PDS) in the year 2008".
2007
“TEAM EXCELLENCE AWARD”. From the Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services. Citation “For developing the adult suicidality database consisting of nearly 400 trials and completing a meta-analysis of the database for a December, 2006 Advisory Committee meeting.”
“SPECIAL RECOGNITION AWARD”. From the Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services. Citation “For advancement of pre-market safety review through the development of a Novel CDER Education Program entitled, {The Safety Dance, A Practical Approach to Pre-market Safety Review}”
2006
“FDA OUTSTANDING SERVICE AWARD”. From the Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services. Citation “For significant contribution to the public health, through superior data analysis and epidemiologic evaluation of FDA's first directly accessed electronic medical records database.”
2005
“FRANCES O. KELSEY DRUG SAFETY EXCELLENCE AWARD” representing Office of Drug Safety. From the Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services. Citation “For demonstrating exceptional expertise and dedication to FDA mission through conduct of analyses describing the risks of suicidality in children from clinical trials of antidepressants.”
“FRANCES O. KELSEY DRUG SAFETY EXCELLENCE AWARD” representing the Division of the Neuropharmacological Drug Products. From the Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services. Citation “For sustained commitment to improving the public health through in-depth evaluation of drug safety issues arising during the drug development process and the post-marketing period.”
“TEAM EXCELLENCE AWARD” from the Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services. Citation “For rationally classifying possible suicide-related adverse events in 23 pediatric antidepressants trials and completing a meta-analysis of the data for a September, 2004 Advisory Committee Meeting.”
2004
“CDER SPECIAL RECOGNITION AWARD” from the Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services. Citation “For demonstrating an exceptional commitment to the public health through conduct of a meta-analysis of suicidality in pediatric trials of antidepressants.”
“SCIENTIFIC ACHIEVEMENT AWARD: EXCELLENCE IN ANALYTICAL SCIENCE” representing the Center for Drug Evaluation and Research. From the Office of Science and Health Coordination, Food and Drug Administration, Department of Health and Human Services. Citation “For developing and applying a novel approach to the analysis of NDA safety data in order to explore a vexing ethical dilemma in antidepressant trial design.”
2002
“EXCELLENCE IN MENTORING AWARD” from the Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services. Citation “For providing the Division of Neuropharmacological Drug Products with a series of informative talks on epidemiological principles and issues related to Patient Reported Outcomes in clinical trials.”
2001
“SPECIAL HONOR CITATION” from the Director of the Center for Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Services. Citation “For sustained superior performance in timely review of an unprecedented volume of new molecular entities while maintaining outstanding review quality and introducing innovative procedures to further enhance quality.”
1993
“AWARD OF RECOGNITION” for outstanding academic performance, published in the 16th Annual Edition of the National Dean's List.
“CERTIFICATE OF ACHIEVEMENT” in Medical Informatics. Division of Medical Informatics, Department of Epidemiology & Preventive Medicine, University of Maryland School of Medicine. Certificate requirements included special studies in Biomedical Computer Science, Neural Networks Methodology and Database Design & Management.
1992
“CLASS VALEDICTORIAN" on more than 60 classmates at the end of a full academic year of postgraduate studies in statistics and mathematics. Institute of Statistical Research and Studies, Cairo University (Egypt)
1986
Graduated with Honors (Dean’s list) from Cairo University School of Medicine. Awarded for sustained and distinguished academic performance in all years of medical school.